skip to main content
Give

Dr. Jeremy Wood's Lab

Research Focus

The Wood laboratory is interested in the processes that regulate the formation and destruction of blood clots. We study this process both in the context of healthy clots that prevent bleeding (“hemostasis”) and unhealthy clots that block blood flow and cause life-threatening tissue damage (“thrombosis”). As all chronic diseases are associated with either increased risk of bleeding or thrombosis, we are also interested in the dysfunctions of this system that occur during disease. By increasing our understanding of these processes, we hope to develop new, safer antithrombotic and pro-hemostatic therapeutic strategies.

Current research focuses include:

  1. Functions and regulation of the anticoagulant Protein S. Protein S is one of the most abundant proteins in the blood and is commonly reduced during inflammation. We recently identified an interaction between Protein S and Von Willebrand Factor (VWF), which is commonly increased during inflammation. We are now studying how these proteins interact and the effect that VWF has on Protein S function. These studies also include the roles of blood cells, such as platelets, endothelial cells, and monocytes/macrophages, in regulating this process.
  2. Mechanisms of inflammation-associated thrombosis. Thrombosis is a common complication of systemic viral infections, such as HIV and SARS-CoV-2. We are working to understand how these infections alter the systems that control clot formation and lysis, to improve the tools available to identify patients most at risk for clots and to provide more targeted therapies.
  3. Novel mechanisms of bleeding. More than half of patients seen for bleeding disorders are ultimately undiagnosed, or diagnosed with “bleeding of unknown cause.” Due to the lack of mechanistic understanding, these patients often have limited available treatments. We are working with clinicians and patients to identify novel mechanisms of bleeding and design targeted treatments.
  4. Thrombolytic resistance in stroke. We are collaborating with clinicians and basic scientists to develop strategies to predict which stroke patients are most likely to respond, or not respond, to thrombolytic intervention.


 

Recent Publications

Original Research Articles
  1. Chanzu, H., Lykins, J., Wigna-Kumar, S., Joshi, S., Pokrovskaya, I., Storrie, B., Pejler, G., Wood, J.P., and Whiteheart, S.W. Platelet α-Granule Cargo Packaging and Release are Affected by the Luminal Proteoglycan, Serglycin. J Thromb Haemost 19 (4): 1082-95, 2021.
  2. Hubbard, W.B., Sim, M.M.S., Saatman, K.E., Sullivan, P.G., and Wood, J.P. Tissue Factor Release Following Traumatic Brain Injury Produces Elevated Thrombin. Res Pract Thromb Haemost 6 (4): e12734, 2022.
  3. Sim, M.M.S., Banerjee, M., Myint, T., Garvy, B.A., Whiteheart, S.W., and Wood, J.P. Total Plasma Protein S Is a Prothrombotic Marker in People Living with HIV. J Acquir Immune Defic Syndrom 90 (4): 463-71, 2022.
  4. Zhang, Y., Wu, C., Li, L., Pandeya, A., Zhang, G., Cui, J., Kirchhofer, D., Wood, J.P., Smyth, S.S., Wei, Y., and Li, Z. Extracellular Histones Trigger Disseminated Intravascular Coagulation by Lytic Cell Death. Int J Mol Sci. 23 (12): 6800, 2022.
  5. Gul, M.H., Htun, Z.M., de Jesus Perez, V., Suleman, M., Arshad, S., Imran, M., Vyasabattu, M., Wood, J.P., Anstead, M., and Morris, P.E. Predictors and Outcomes of Acute Pulmonary Embolism in COVID-19; Insights from US National COVID Cohort Collaborative. Resp Res 24 (1): 59, 2023.
  6. Zhang, Z., Dai, W., Zhu, W., Rodriguez, M., Lund, H., Xia, Y., Chen, Y., Rau, M., Schneider, E.A., Graham, M.B., Jobe, S., Wang, D., Cui, W., Wen, R., Whiteheart, S.W., Wood, J.P., Silverstein, R., Berger, J.S., Baumann Kreuziger, L., Barrett, T.J., and Zheng, Z. Plasma Tissue-Type Plasminogen Activator Is Associated with Lipoprotein(a) and Clinical Outcomes in Hospitalized Patients with COVID-19. Res Pract Thromb Haemost 7:102164, 2023.
  7. Li, X., Song, X., D Mahmood, D.F., Sim, M.M.S., Bidarian, S.J., and Wood, J.P. Activated Protein C, Protein S, and Tissue Factor Pathway Inhibitor Cooperate to Inhibit Thrombin Activation. Thromb Res. 230:84-93, 2023.
  8. Matharu, S.S., Nordmann, C.S., Ottman, K.R., Akkem, R., Palumbo, D., Cruz, D.R.D., Campbell, K., Sievert, G., Sturgill, J., Porterfield, J.Z., Joshi, S., Alfar, H.R., Peng, C., Pokrovskaya, I.D., Kamykowski, J.A., Wood, J.P., Garvy, B., Aronova, M.A., Whiteheart, S.W., Leapman, R.D., and Storrie, B. Deep Learning, 3D Ultrastructural Analysis Reveals Quantitative Differences in Platelet and Organelle Packing in COVID-19/SARSCoV2 Patient Derived Platelets. 34:2264978, 2023.
  9. Erlandson, K.M., Geng, L.N., Selvaggi, C.A., …, Marshall, G.D., Wood, J., Warren, D., Horwitz, L., Foulkes, A.S., and McComsey, G.A. (59 authors). Post-Acute Standard Clinical Laboratory Measurements Do Not Differentiate Prior SARS-CoV-2 Infection and Post-Acute Sequelae among Adults in the RECOVER Cohort. Annals Int Med. 329:1934-46, 2024.
  10. Sim, M.M.S., Alfar, H.R., Hollifield, M., Chung, D.W., Fu, X., Gandhapudi, S., Banerjee, M., Peng, C., Li, X., Thornton, A.C., Porterfield, J.Z., Sturgill, J.L., Sievert, G.A., Barton-Baxter, M., Campbell, K.S., Woodward, J.G., Lopez, J.A., Whiteheart, S.W., Garvy, B.A., and Wood, J.P. Unfolded Von Willebrand Factor Binds Protein S and Reduces Anticoagulant Activity. Blood Vess Thromb Hemost. 2(1): 100030, 2025.
  11. Cui J., Li, H., Ye, D., Zhang, G., Zhang, Y., Yang, L., Sim, M.M.S., Wood, J.P., Wei, Y., Li, Z., and Wu, C. Inhibiting NINJ1-dependent Plasma Membrane Rupture Protects Against Inflammasome-induced Blood Coagulation and Inflammation. 12: RP91329, 2025.
  12. Alfar, H.R., Driehaus, E.R., Smith, A.N., Coenen, D.M., D Mahmood, D.F., Wood, J.P., and Whiteheart, S.W. (2025) Role of Rubicon in Platelets: Promoter of Thrombosis and Not Autophagy Repression. Blood Adv 10(4): 1413-25, 2026.
Reviews, Commentaries, and Editorials

 

  1. Wood, J.P. Factor VIIa Is Not Just a Factor X Activator. Blood 137 (24): 3324-5, 2021.
  2. Milstone, L.M., Jackson, C., Becker, R.C., Camire, R., Knabb, R., Mann, K., Ruf, W., Wexler, R.R., and Wood, J. Discussion of talks from the symposium: Factor X: From thrombokinase to oral anti‑coagulants and beyond. J Thromb Thrombolys. 52 (2): 408-13, 2021.
  3. Sim, M.M.S. and Wood, J.P. Dysregulation of Protein S in COVID-19. Best Pract & Res Clin Haematol. 35 (3): 101376, 2022.
  4. Sim, M.M.S., Shiferawe, K., and Wood, J.P. Novel Strategies in Antithrombotic Therapy: Targeting Thrombosis while Preserving Hemostasis. Front Cardiovasc Med. 10: 1272971, 2023.
  5. Wood, J.P. Paving the Way to Factor X Deficiency Therapies. Blood. 144 (2): 134-5, 2024.
  6. Wood, J.P. and Khasawneh, F.T. Clot Formation: Novel Regulators, Drugs and Targets. J Pharmacol Exp Therap. 392 (10): 103707, 2025.

 

Lab Funding
Current Funding:

Title: Mechanisms of Thrombosis in SARS CoV-2 Infection (1R01HL172844)

The goal of this study is to understand the biochemical mechanisms of thrombosis in acute and post-acute SARSCoV-2 infection.

Title: The Role of LDL in Hemostasis (1R01HL174609)

The goal of this study is to understand the contributions of LDL and LDL-associated proteins to hemostasis in healthy individuals and individuals with Hemophilia A.

Recently Completed Funding

Title: Post-Acute Sequelae of SARS-CoV-2 Infection Initiative: NYU Langone Health Clinical Science Core, Data Resource Core, and PASC Biorepository Core (1OT2HL161847)

The goal of this study was to define the prevalence and phenotype(s) associated with post-COVID syndrome.

Title: Thrombosis Assays for STOP PASC Clinical Trial (PI) (Funded by Pfizer, Inc.)

The goal of this study was to measure markers of thrombosis in participants in the STOP-PASC clinical trial.

Title: Impact of the Y285C prothrombin variant on coagulation and hemostasis, and investigations into treatment (co-PI) (Funded by Versiti Research Foundation)

The goal of this study was to identify the biochemical cause of bleeding in a family with a history of unexplained bleeding.

Title: Coordination of the TFPI/Protein S and APC/Protein S Anticoagulant Systems (PI) (Funded by Pfizer, Inc.)

The goal of this study was to understand how protein S coordinates the anticoagulant activities of tissue factor pathway inhibitor and activated protein C.

Lab Members

Dr. Mélissa Jauquet

Dr. Jauquet

  Dr. Narges Mehrpour